Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.44 |
| ▸ | MC1R | Q01726 | 2/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357303 | 0.86 | LTA4H (0.48) | SMN1; SMN2SIGMAR1SLC18A2MC4RMC1R | |
| SCHEMBL2030876 | 0.83 | CYP1A2 (0.73) | CYP1A2SMN1; SMN2CYP2C19GRM2GRM3 | |
| SCHEMBL29642918 | 0.83 | CYP1A2 (0.73) | CYP1A2SMN1; SMN2CYP2C19GRM2GRM3 | |
| SCHEMBL1818814 | 0.83 | CYP1A2 (0.73) | CYP1A2SMN1; SMN2CYP2C19GRM2GRM3 | |
| SCHEMBL29412325 | 0.83 | CYP1A2 (0.73) | CYP1A2SMN1; SMN2CYP2C19GRM2GRM3 | |
| SCHEMBL2982368 | 0.79 | HRH3 (0.64) | CYP1A2SMN1; SMN2CYP2C19CD274 | |
| SCHEMBL27206530 | 0.76 | CYP2C19 (0.78) | CYP1A2SMN1; SMN2CYP2C19MC4RMC1R | |
| SCHEMBL27191663 | 0.76 | CYP2C19 (0.78) | CYP1A2SMN1; SMN2CYP2C19MC4RMC1R | |
| SCHEMBL27191675 | 0.76 | CYP2C19 (0.78) | CYP1A2SMN1; SMN2CYP2C19MC4RMC1R | |
| SCHEMBL1116547 | 0.76 | ALDH1A1 (0.56) | CYP1A2SMN1; SMN2CYP2C19GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | CYP1A2 2257/4885SMN1; SMN2 3087/4885CYP2C19 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.